

Supplementary Table 1. Studies excluded from quantitative analysis with reasons for exclusion

Year of Publication	Last name of first author	Reason excluded
1976	Armstrong [60]	Wrong measure of effect (proportionate mortality)
1986	Vodvarzhka [61]	Wrong measure of effect (proportionate mortality)
2004	Coughlin [62]	Duplicate of Campbell 2012
2009	Tseng [63]	Wrong measure of effect (proportionate mortality)
2010	Zhou [64]	Kidney and Bladder Cancer grouped together
2011	Hwang [65]	Duplicate population of Ahn 2016
2011	Rao Kondapally Seshasai [66]	Wrong measure of effect (proportionate mortality)
2012	Campbell [67]	Wrong measure of effect (proportionate mortality)
2014	Romero [68]	Cross-sectional data
2014	Gandaglia [69]	Wrong outcome (perioperative mortality only - 30-day mortality after RC)
2015	Goossens [70]	Wrong measure of effect (proportionate mortality)
2016	Ozer [71]	Wrong measure of effect (relapse frequency)
2016	Saito [72]	Incompatible measure of effect (population attributable fraction, observed incidence/ mortality, predicted incidence/mortality)
2016	Chen [73]	Vulnerable to extreme selection bias (hospital patients with diagnosis of DM or bladder cancer)
2017	Froehner [74]	Wrong measure of effect (competing mortality)
2018	Lenis [75]	Combined estimate for recurrence/ progression
2018	Bjornsdottir [76]	Wrong measure of effect (proportionate mortality)
2019	Yu [77]	Duplicate population of Ahn 2016, Abstract only

REFERENCES

59. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. *Am J Epidemiol* 1992;135:1301-9.
60. Armstrong B, Lea AJ, Adelstein AM, Donovan JW, White GC, Ruttel S. Cancer mortality and saccharin consumption in diabetics. *Br J Prev Soc Med* 1976;30:151-7.
61. Vodvarzhka P, Villaskhek I, Gold O, Kozubek S. Does diabetes affect probability of cure and prolongation of life of oncological patients? *Med Radiol (Mosk)* 1986;31:25-8.
62. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. *Am J Epidemiol* 2004;159:1160-7.
63. Tseng CH, Chong CK, Tseng CP, Chan TT. Age-related risk of mortality from bladder cancer in diabetic patients: a 12-year follow-up of a national cohort in Taiwan. *Ann Med* 2009;41:371-9.
64. Zhou XH, Qiao Q, Zethelius B, Pyörälä K, Söderberg S, Pajak A, et al. Diabetes, prediabetes and cancer mortality. *Diabetologia* 2010;53:1867-76.
65. Hwang EC, Kim YJ, Hwang IS, Hwang JE, Jung SI, Kwon DD, et al. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. *Int J Urol* 2011;18:769-76.
66. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med* 2011;364:829-41.
67. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. *Diabetes Care* 2012;35:1835-44.
68. Romero V, Peyton C, Gray I, Hemal A, Terlecki R. Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use. *BMC Urol* 2014;14:10.
69. Gandaglia G, Popa I, Abdollah F, Schiffmann J, Shariat SF, Briganti A, et al. The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study. *Eur Urol* 2014;66:561-8.
70. Goossens ME, Zeegers MP, Bazelier MT, De Bruin ML, Buntinx F, de Vries F. Risk of bladder cancer in patients with diabetes: a retrospective cohort study. *BMJ Open* 2015;5:e007470.
71. Ozer K, Horsanali MO, Gorgel SN, Ozbek E. Diabetes is an important risk factor for metastasis in non-muscle-invasive bladder cancer. *Asian Pac J Cancer Prev* 2016;17:105-8.
72. Saito E, Charvat H, Goto A, Matsuda T, Noda M, Sasazuki S, et al. Burden of cancer associated with type 2 diabetes mellitus in Japan, 2010-2030. *Cancer Sci* 2016;107:521-7.
73. Chen JY, Chiou WK, Chou WY, Lin JD. The impact of type 2 diabetes mellitus on mortality in hospitalized female cancer patients in Taiwan. *Asia Pac J Clin Oncol* 2016;12:e75-81.
74. Froehner M, Koch R, Heberling U, Novotny V, Hubler M, Wirth MP. An easily applicable single condition-based mortality index for patients undergoing radical prostatectomy or radical cystectomy. *Urol Oncol* 2017;35:32.e17-32.e23.
75. Lenis AT, Asanad K, Blaibel M, Donin NM, Chamie K. Association between metabolic syndrome and recurrence

- of nonmuscle invasive bladder cancer following bacillus Calmette-Guerin treatment. *Urol Pract* 2018;5:132-38.
76. Bjornsdottir HH, Franzén S, Rawshani A, Sattar N, Svensson AM, Gudbjornsdottir S. Cancer incidence and mortality among 457,473 persons with type 2 diabetes compared to 2,287,365 matched controls in Sweden: An observational study. *Diabetologia* 2018;61:S591.
77. Yu SH, Oh JY, Eun SJ, et al. Impact of glycemic control on the recurrence and progression of non-muscle invasive bladder cancer in patients with diabetes mellitus. *International Journal of Urology*. 2019;26:12-13.